Grimm, M., Amsberg, G. V., Heers, H., Degener, S., Roghmann, F., Casuscelli, J., Rausch, S., Augustin, M., Haeberle, L., Leucht, K., Roessler, A., Zengerling, F. (2026). 3-weekly docetaxel 75 mg/m
                    <sup>2</sup>
                    vs 2-weekly docetaxel 50 mg/m
                    <sup>2</sup>
                    in combination with darolutamide + ADT in patients with mHSPC: Subgroup analyses from the randomised phase 3 ARASAFE trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.7_suppl.153